478540-98-6

Upstream product

• 100-39-0 benzyl bromide 
• 328918-84-9 2-(4-bromophenyl)-5-methyl-4-oxazoleethanol 

Downstream Products

• 478541-04-7 4-(2-benzyloxy-ethyl)-5-methyl-2-(4-phenoxy-phenyl)-oxazole 
• 478540-99-7 {4-[4-(2-benzyloxy-ethyl)-5-methyl-oxazol-2-yl]-phenyl}-methyl-phenyl-amine 
• 478542-55-1 3-(2-(isopropoxycarbonylamino-methyl)-4-{2-[5-methyl-2-(4-phenoxy-phenyl)-oxazol-4-yl]-ethoxy}-phenyl)-propionic acid tert-butyl ester 
• 478541-03-6 toluene-4-sulfonic acid 2-[5-methyl-2-(4-phenoxy-phenyl)-oxazol-4-yl]-ethyl ester 
• 874365-60-3 2-[5-methyl-2-(4-phenoxy-phenyl)-oxazol-4-yl]-ethanol 

Relevant academic research and scientific papers

Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands

PPAR ligands with varied subtype selectivity have been synthesized using an achiral aminomethyl dihydrocinnamate template. Several compounds in this series have demonstrated potent plasma glucose and triglyceride lowering capability in rodent models of type 2 diabetes.

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.